Skip to main content
Premium Trial:

Request an Annual Quote

U. of Liverpool Awarded $33.5M to Build Personalized Medicine Incubator Space

NEW YORK (GenomeWeb) – The University of Liverpool said on Wednesday that it has been awarded about £20.5 million ($33.5 million) to build an incubator space for small and medium-sized businesses operating in the personalized medicine arena.

The Liverpool Bio Innovation Hub will encompass more than 6,000 square meters and will include laboratory and office space, allowing commercial access to biobank technologies and genomic, proteomic, and metabolomic equipment.

Munir Pirmohamed, head of the Wolfson Centre for Personalised Medicine, said in a statement that the Bio Hub will facilitate collaboration between the university, the UK's National Health Service partners, and industry "to ensure that medical research is translated effectively into outputs that will benefit patients. It provides industry with access to expertise, biosamples, and high-end equipment, as well as opportunities for researchers to work with commercial enterprises."

The space is anticipated to open next year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.